On September 19, 2025, AIVIS Inc. announced that its joint research on artificial intelligence (AI) for predicting colorectal cancer prognosis received the First Best Poster Prize at the European Congress of Pathology (ECP) 2025.

The study was conducted in collaboration with Korea University Guro Hospital (Professor Jongwon Lee) and Asan Medical Center (Professor Seungmo Hong). Leveraging the AIVIS pathology image analysis platform, Qanti®Discovery, the research achieved two key milestones:

• Prognostic biomarker prediction: The AI model predicted expression of LRRC15, a biomarker associated with colorectal cancer prognosis, directly from standard H&E slides with 88% accuracy—potentially eliminating the need for costly special stains.
• Stage prediction: The same model demonstrated high accuracy in predicting critical staging parameters, including tumor invasion and lymph node status, expanding the role of AI in pathology beyond prognosis to staging support.

The ability to derive both prognostic and staging information from routine H&E slides is regarded as a major advancement in the application of AI to pathology diagnostics.

Daehong Lee, CEO of AIVIS, stated:

“This award highlights the clinical value of our AI technology, globally recognized through collaboration with leading domestic researchers. From prognosis to staging, we are committed to setting new standards in pathology diagnostics with AI and contributing to the advancement of precision medicine.”

About AIVIS

AIVIS is a South Korea-based medical AI company driving innovation in digital pathology. Its flagship solution, Qanti IHC, provides automated quantification of key biomarkers—including ER, PR, HER2, and Ki-67—with exceptional capability in detecting HER2-low and ultralow cases. Backed by MFDS approval and a growing global presence, AIVIS is dedicated to advancing diagnostic accuracy and enabling AI-powered precision medicine worldwide.